Anthony W. Stowers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anthony W. Stowers has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
David C. Kaslow
Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Rockville, MD 20852; and ‡Genzyme Transgenics Corporation, Framingham, MA 01701-9322
5 shared publicationsLouis H. Miller
Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland
4 shared publicationsCarole A. Long
Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland
3 shared publications- Allan Saul
The Burnet Institute, Melbourne, Australia
2 shared publications Hajime Hisaeda
Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases/NIH, Rockville, MD 20852, USA
2 shared publicationsMichael C. Kennedy
Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland
2 shared publications
Latest Publications
- Open Access
- 1 March 2002
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 185 (5) , 657-664
Merozoite Surface Protein 3 and Protection against Malaria inAotus nancymaiMonkeys
A blood-stage vaccine based on Plasmodium falciparum merozoite surface protein 3 (MSP3) was tested for efficacy in a primate model. Aotus nancymai mo
- 1 March 2002
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 185 (5) , 657-664
Open AccessMerozoite Surface Protein 3 and Protection against Malaria inAotus nancymaiMonkeys
A blood-stage vaccine based on Plasmodium falciparum merozoite surface protein 3 (MSP3) was tested for efficacy in a primate model. Aotus nancymai mo
- Open Access
- 18 December 2001
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 99 (1) , 339-344
A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum
Two strains of transgenic mice have been generated that secrete into their milk a malaria vaccine candidate, the 42-kDa C-terminal portion of Plasmodium falciparum merozoite surface protein 1 (MSP1 42 ). One strain secretes an MSP1 42 with an amino acid sequence homologous to that of the FVO parasite line, the other an MSP1 42 where two putative N-linked glycosylation sites in the FVO sequence have been removed. Both forms of MSP1 42 were purified from whole milk to greater than 91% homogeneity at high yields. Both proteins are recognized by a panel of monoclonal antibodies and have identical N termini, but are clearly distinguishable by some biochemical properties. These two antigens were each emulsified with Freund's adjuvant and used to vaccinate Aotus nancymai monkeys, before challenge with the homologous P. falciparum FVO parasite line. Vaccination with a positive control molecule, a glycosylated form of MSP1 42 produced in the baculovirus expression system, successfully protected five of six monkeys. By contrast, vaccination with the glycosylated version of milk-derived MSP1 42 conferred no protection compared with an adjuvant control. Vaccination with the nonglycosylated, milk-derived MSP1 42 successfully protected the monkeys, with 4/5 animals able to control an otherwise lethal infection with P. falciparum compared with 1/7 control animals. Analysis of the different vaccines used suggested that the differing nature of the glycosylation patterns may have played a critical role in determining efficacy. This study demonstrates the potential for producing efficacious malarial vaccines in transgenic animals.
- 18 December 2001
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 99 (1) , 339-344
Open AccessA recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum
Two strains of transgenic mice have been generated that secrete into their milk a malaria vaccine candidate, the 42-kDa C-terminal portion of Plasmodium falciparum merozoite surface protein 1 (MSP1 42 ). One strain secretes an MSP1 42 with an amino acid sequence homologous to that of the FVO parasite line, the other an MSP1 42 where two putative N-linked glycosylation sites in the FVO sequence have been removed. Both forms of MSP1 42 were purified from whole milk to greater than 91% homogeneity at high yields. Both proteins are recognized by a panel of monoclonal antibodies and have identical N termini, but are clearly distinguishable by some biochemical properties. These two antigens were each emulsified with Freund's adjuvant and used to vaccinate Aotus nancymai monkeys, before challenge with the homologous P. falciparum FVO parasite line. Vaccination with a positive control molecule, a glycosylated form of MSP1 42 produced in the baculovirus expression system, successfully protected five of six monkeys. By contrast, vaccination with the glycosylated version of milk-derived MSP1 42 conferred no protection compared with an adjuvant control. Vaccination with the nonglycosylated, milk-derived MSP1 42 successfully protected the monkeys, with 4/5 animals able to control an otherwise lethal infection with P. falciparum compared with 1/7 control animals. Analysis of the different vaccines used suggested that the differing nature of the glycosylation patterns may have played a critical role in determining efficacy. This study demonstrates the potential for producing efficacious malarial vaccines in transgenic animals.
- 1 September 2001
- Published by Elsevier in Trends in Parasitology
- Vol. 17 (9) , 415-419
Are trials in New World monkeys on the critical path for blood-stage malaria vaccine development?
- 1 September 2001
- Published by Elsevier in Trends in Parasitology
- Vol. 17 (9) , 415-419
Are trials in New World monkeys on the critical path for blood-stage malaria vaccine development?
- 1 March 2001
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 69 (3) , 1536-1546
Efficacy of Two Alternate Vaccines Based onPlasmodium falciparumMerozoite Surface Protein 1 in anAotusChallenge Trial
In an attempt to produce a more defined, clinical-grade version of a vaccine based onPlasmodium falciparummerozoite surface protein 1 (MSP1), we evaluated the efficacy of two recombinant forms of MSP1 in anAotus nancymaichallenge model system. One recombinant vaccine, bvMSP142, based on the 42-kDa C-terminal portion of MSP1, was expressed as a secreted protein in baculovirus-infected insect cells. A highly pure baculovirus product could be reproducibly expressed and purified at yields in excess of 8 mg of pure protein per liter of culture. This protein, when tested for efficacy in theAotuschallenge model, gave significant protection, with only one of seven monkeys requiring treatment for uncontrolled parasitemia after challenge withP. falciparum. The second recombinant protein, P30P2MSP119, has been used in previous studies and is based on the smaller, C-terminal 19-kDa portion of MSP1 expressed inSaccharomyces cerevisiae. Substantial changes were made in its production process to optimize expression. The optimum form of this vaccine antigen (as judged by in vitro and in vivo indicators) was then evaluated, along with bvMSP142, for efficacy in theA. nancymaisystem. The new formulation of P30P3MSP119performed significantly worse than bvMSP142and appeared to be less efficacious than we have found in the past, with four of seven monkeys in the vaccinated group requiring treatment for uncontrolled parasitemia. With both antigens, protection was seen only when high antibody levels were obtained by formulation of the vaccines in Freund's adjuvant. Vaccine formulation in an alternate adjuvant, MF59, resulted in significantly lower antibody titers and no protection.
- 1 March 2001
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 69 (3) , 1536-1546
Efficacy of Two Alternate Vaccines Based onPlasmodium falciparumMerozoite Surface Protein 1 in anAotusChallenge Trial
In an attempt to produce a more defined, clinical-grade version of a vaccine based onPlasmodium falciparummerozoite surface protein 1 (MSP1), we evaluated the efficacy of two recombinant forms of MSP1 in anAotus nancymaichallenge model system. One recombinant vaccine, bvMSP142, based on the 42-kDa C-terminal portion of MSP1, was expressed as a secreted protein in baculovirus-infected insect cells. A highly pure baculovirus product could be reproducibly expressed and purified at yields in excess of 8 mg of pure protein per liter of culture. This protein, when tested for efficacy in theAotuschallenge model, gave significant protection, with only one of seven monkeys requiring treatment for uncontrolled parasitemia after challenge withP. falciparum. The second recombinant protein, P30P2MSP119, has been used in previous studies and is based on the smaller, C-terminal 19-kDa portion of MSP1 expressed inSaccharomyces cerevisiae. Substantial changes were made in its production process to optimize expression. The optimum form of this vaccine antigen (as judged by in vitro and in vivo indicators) was then evaluated, along with bvMSP142, for efficacy in theA. nancymaisystem. The new formulation of P30P3MSP119performed significantly worse than bvMSP142and appeared to be less efficacious than we have found in the past, with four of seven monkeys in the vaccinated group requiring treatment for uncontrolled parasitemia. With both antigens, protection was seen only when high antibody levels were obtained by formulation of the vaccines in Freund's adjuvant. Vaccine formulation in an alternate adjuvant, MF59, resulted in significantly lower antibody titers and no protection.
- 1 December 2000
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 68 (12) , 6618-6623
Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability ofPlasmodium vivaxTo Infect Mosquitoes
Transmission-blocking vaccines are one strategy for controlling malaria, whereby sexual-stage parasites are inhibited from infecting mosquitoes by human antibodies. To evaluate whether the recently clonedPlasmodium vivaxproteins Pvs25 and Pvs28 are candidates for a transmission-blocking vaccine, the molecules were expressed in yeast as secreted recombinant proteins. Mice vaccinated with these proteins adsorbed to aluminum hydroxide developed strong antibody responses against the immunogens, although for Pvs28, this response was genetically restricted. Antisera against both recombinant Pvs25 and Pvs28 recognized the corresponding molecules expressed by cultured sexual-stage parasites isolated from patients withP. vivaxmalaria. The development of malaria parasites in mosquitoes was completely inhibited when these antisera were ingested with the infected blood meal. Pvs25 and Pvs28, expressed inSaccharomyces cerevisiae, are as yet the only fully characterized transmission-blocking vaccine candidates againstP. vivaxthat induce such a potent antiparasite response.
- 1 December 2000
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 68 (12) , 6618-6623
Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability ofPlasmodium vivaxTo Infect Mosquitoes
Transmission-blocking vaccines are one strategy for controlling malaria, whereby sexual-stage parasites are inhibited from infecting mosquitoes by human antibodies. To evaluate whether the recently clonedPlasmodium vivaxproteins Pvs25 and Pvs28 are candidates for a transmission-blocking vaccine, the molecules were expressed in yeast as secreted recombinant proteins. Mice vaccinated with these proteins adsorbed to aluminum hydroxide developed strong antibody responses against the immunogens, although for Pvs28, this response was genetically restricted. Antisera against both recombinant Pvs25 and Pvs28 recognized the corresponding molecules expressed by cultured sexual-stage parasites isolated from patients withP. vivaxmalaria. The development of malaria parasites in mosquitoes was completely inhibited when these antisera were ingested with the infected blood meal. Pvs25 and Pvs28, expressed inSaccharomyces cerevisiae, are as yet the only fully characterized transmission-blocking vaccine candidates againstP. vivaxthat induce such a potent antiparasite response.
- Open Access
- 1 October 2000
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 68 (10) , 5530-5538
A Region ofPlasmodium falciparumAntigen Pfs25 That Is the Target of Highly Potent Transmission-Blocking Antibodies
Each of the four epidermal growth factor (EGF)-like domains of thePlasmodium falciparumsexual-stage antigen Pfs25 has been individually expressed as a yeast-secreted recombinant protein (yEGF1 through yEGF4). All four are recognized by the immune sera of animals and humans vaccinated with TBV25H (the corresponding yeast-secreted full-length recombinant form of Pfs25), with antibody titers to yEGF1 and yEGF2 weakly correlating with the ability of the sera to block the transmission of parasites to the mosquito host. All four proteins are poorly immunogenic in mice vaccinated with aluminum hydroxide-absorbed formulations. However, all four successfully primed the mice to mount an effective secondary antibody response after a single boost with TBV25H. Sera from mice vaccinated with yEGF2-TBV25H completely block the development of oocysts in mosquito midguts in membrane-feeding assays. Further, of the four proteins, only the depletion of antibodies to yEGF2 from the sera of rabbits vaccinated with TBV25H consistently abolished the ability of those sera to block oocyst development. Thus, antibodies to the second EGF-like domain of Pfs25 appear to mediate a very potent blocking activity, even at low titers. Vaccination strategies that target antibody response towards this domain may improve the efficacy of future transmission-blocking vaccines.
- 1 October 2000
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 68 (10) , 5530-5538
Open AccessA Region ofPlasmodium falciparumAntigen Pfs25 That Is the Target of Highly Potent Transmission-Blocking Antibodies
Each of the four epidermal growth factor (EGF)-like domains of thePlasmodium falciparumsexual-stage antigen Pfs25 has been individually expressed as a yeast-secreted recombinant protein (yEGF1 through yEGF4). All four are recognized by the immune sera of animals and humans vaccinated with TBV25H (the corresponding yeast-secreted full-length recombinant form of Pfs25), with antibody titers to yEGF1 and yEGF2 weakly correlating with the ability of the sera to block the transmission of parasites to the mosquito host. All four proteins are poorly immunogenic in mice vaccinated with aluminum hydroxide-absorbed formulations. However, all four successfully primed the mice to mount an effective secondary antibody response after a single boost with TBV25H. Sera from mice vaccinated with yEGF2-TBV25H completely block the development of oocysts in mosquito midguts in membrane-feeding assays. Further, of the four proteins, only the depletion of antibodies to yEGF2 from the sera of rabbits vaccinated with TBV25H consistently abolished the ability of those sera to block oocyst development. Thus, antibodies to the second EGF-like domain of Pfs25 appear to mediate a very potent blocking activity, even at low titers. Vaccination strategies that target antibody response towards this domain may improve the efficacy of future transmission-blocking vaccines.